Physician profile
Piush Gupta
NPI 1235114075
$2,300.47
in general payments reported to CMS, 2019-2025
21 companies · $482 in 2025
The $482 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $81.16 · 2021: $32.73 · 2022: $149 · 2023: $597 · 2024: $695 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $867.66 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $232.14 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $207.99 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.69 | 2019-2025 | Xifaxan |
| Qol Medical, LLC | $151.30 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $121.65 | 2023-2024 | Dupixent |
| Pfizer INC. | $110.22 | 2019-2025 | |
| Janssen Biotech, INC. | $88.35 | 2023-2025 | Stelara, Tremfya |
| Celgene Corporation | $53.36 | 2023-2024 | Zeposia |
| Braintree Laboratories, INC. | $37.16 | 2020-2022 | |
| Celltrion USA INC. | $37.05 | 2025 | Vegzelma |
| Gilead Sciences, INC. | $31.90 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $29.65 | 2019-2024 | |
| Exact Sciences Corporation | $22.50 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $21.88 | 2023 | Amjevita, Avsola |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $20.02 | 2025 | Hadlima, Renflexis |
| Intercept Pharmaceuticals, INC. | $16.59 | 2023 | Ocaliva |
| Fresenius Kabi USA, LLC | $16.08 | 2024 | Idacio |
| Novo Nordisk INC | $15.36 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $13.05 | 2019 | |
| Merck Sharp & Dohme LLC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Piush Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.